Treatment of severe psoriasis with infliximab

Treatment of severe psoriasis with infliximab

JA Leman, AD BurdenAlan Lyell Centre for Dermatology, Western Infirmary, Glasgow, UKAbstract: Psoriasis is a chronic, immune mediated inflammatory disease characterized by increased cell signalling via cytokines and chemokines on a background of up-regulated gene expression. There is substantial evi...

Full description

Bibliographic Details
Main Authors: JA Leman, AD Burden
Format: Article
Language:English
Published: Dove Medical Press 2008-11-01
Series:Therapeutics and Clinical Risk Management
Online Access:http://www.dovepress.com/treatment-of-severe-psoriasis-with-infliximab-a2635
id doaj-dd29f282f5b94b018e83f24850da344b
record_format Article
spelling doaj-dd29f282f5b94b018e83f24850da344b2020-11-24T22:05:51ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2008-11-012008Issue 611651175Treatment of severe psoriasis with infliximabJA LemanAD BurdenJA Leman, AD BurdenAlan Lyell Centre for Dermatology, Western Infirmary, Glasgow, UKAbstract: Psoriasis is a chronic, immune mediated inflammatory disease characterized by increased cell signalling via cytokines and chemokines on a background of up-regulated gene expression. There is substantial evidence that psoriasis should be regarded as more than a cutaneous disease; major psychological morbidity and increased mortality from cardiovascular disease and cancer are increasingly recognized. Improved understanding of the genetic and immunological mechanisms underpinning psoriasis has occurred concurrently with the development of targeted biological therapies including infliximab. These newer therapeutic approaches can be very effective but their long term safety profile is not yet fully determined.Keywords: psoriasis, pathogenesis, co-morbidities, treatment, infliximab http://www.dovepress.com/treatment-of-severe-psoriasis-with-infliximab-a2635
collection DOAJ
language English
format Article
sources DOAJ
author JA Leman
AD Burden
spellingShingle JA Leman
AD Burden
Treatment of severe psoriasis with infliximab
Therapeutics and Clinical Risk Management
author_facet JA Leman
AD Burden
author_sort JA Leman
title Treatment of severe psoriasis with infliximab
title_short Treatment of severe psoriasis with infliximab
title_full Treatment of severe psoriasis with infliximab
title_fullStr Treatment of severe psoriasis with infliximab
title_full_unstemmed Treatment of severe psoriasis with infliximab
title_sort treatment of severe psoriasis with infliximab
publisher Dove Medical Press
series Therapeutics and Clinical Risk Management
issn 1176-6336
1178-203X
publishDate 2008-11-01
description JA Leman, AD BurdenAlan Lyell Centre for Dermatology, Western Infirmary, Glasgow, UKAbstract: Psoriasis is a chronic, immune mediated inflammatory disease characterized by increased cell signalling via cytokines and chemokines on a background of up-regulated gene expression. There is substantial evidence that psoriasis should be regarded as more than a cutaneous disease; major psychological morbidity and increased mortality from cardiovascular disease and cancer are increasingly recognized. Improved understanding of the genetic and immunological mechanisms underpinning psoriasis has occurred concurrently with the development of targeted biological therapies including infliximab. These newer therapeutic approaches can be very effective but their long term safety profile is not yet fully determined.Keywords: psoriasis, pathogenesis, co-morbidities, treatment, infliximab
url http://www.dovepress.com/treatment-of-severe-psoriasis-with-infliximab-a2635
work_keys_str_mv AT jaleman treatmentofseverepsoriasiswithinfliximab
AT adburden treatmentofseverepsoriasiswithinfliximab
_version_ 1716598057680764928

Similar Items